2-guanidinothiazole-4-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-guanidinothiazole-4-carboxylic acid
• 英文别名: 2-Guanidino-thiazole-4-carboxylic acid；2-(diaminomethylideneamino)-1,3-thiazole-4-carboxylic acid
• 化学式: C₅H₆N₄O₂S
• 分子量: 186.194
• InChiKey: RGHIROSMHZJRQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  143
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-guanidinothiazole-4-carboxylic acid 、 N-羟基丁二酰亚胺 以66%的产率得到
  参考文献：
  名称：

  SCHNUR, RODNEY C.;FLIRI, ANTON F. J.;KAJIJI, SHAMA;POLLACK, VINCENT A., J. MED. CHEM., 34,(1991) N, C. 914-918

  摘要：

  DOI：
• 作为产物：
  描述：

  2-胍基-4-噻唑羧酸乙酯 在 氢氧化钾 作用下， 反应 0.5h， 生成 2-guanidinothiazole-4-carboxylic acid
  参考文献：
  名称：

  N-(5-fluorobenzothiazol-2-yl)-2-guanidinothiazole-4-carboxamide. A novel, systemically active antitumor agent effective against 3LL Lewis Lung carcinoma

  摘要：

  N-(5-Fluorobenzothiazol-2-yl)-2-guanidinothiazole-4-carboxamide (1) is a member of a series of amides found to substantially increase lifespan in mice bearing established micrometastatic 3LL Lewis lung carcinoma. Amide 1 is effective after either oral or intraperitoneal dosing in acute, subacute, or chronic regimens. 1 is well tolerated in this model with an excellent therapeutic index relative to the cytotoxic anticancer drug adriamycin.

  DOI：

  10.1021/jm00107a007

文献信息

• Thiazole derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06344562B1

  公开（公告）日：2002-02-05

  Compounds of the formula: as well as pharmaceutically usable salts and esters thereof, wherein R1, R2 and R3 have the significance ascribed herein, inhibit binding of adhesive proteins to the surface of different types of cell and accordingly influence cell-cell and cell-matrix interactions. These compounds can be used in the form of pharmaceutical preparations for the control or prevention of neoplasms, tumor metastasing, tumor growth, osteoporosis, Paget's disease, diabetic retinopathy, macular degeneration, restenosis following vascular intervention, psoriasis, arthritis, fibrosis, kidney failure, as well as infection caused by viruses, bacteria or fungi.

  该公式的化合物：以及其药用盐和酯，其中R1、R2和R3具有在此规定的意义，抑制粘附蛋白质与不同类型细胞表面的结合，从而影响细胞-细胞和细胞-基质相互作用。这些化合物可以用作制药制剂的形式，用于控制或预防肿瘤、肿瘤转移、肿瘤生长、骨质疏松症、帕盖特病、糖尿病视网膜病变、黄斑变性、血管介入后再狭窄、银屑病、关节炎、纤维化、肾功能衰竭，以及由病毒、细菌或真菌引起的感染。
• Haloacetyl imidazoles
  申请人：Pfizer Inc.

  公开号：US04452987A1

  公开（公告）日：1984-06-05

  A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

  本发明揭示了一系列2-胍基-4-杂环芳基噻唑化合物，其中杂环芳基取代基选择自噻唑基、三唑基、咪唑基和2-烷基、2-氨基和2-羧酰胺衍生物。这些新型化合物具有抗分泌作用和组胺H.sub.2拮抗剂作用，适用于治疗胃酸过多和消化性溃疡。本发明还揭示了含有这些新型化合物的制药组合物以及使用这些化合物治疗胃酸过多和消化性溃疡的方法。还描述了制备新型抗分泌化合物的新型中间体。
• 2-Guanidino-4-heteroarylthiazoles
  申请人：Pfizer Inc.

  公开号：US04510313A1

  公开（公告）日：1985-04-09

  A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

  本发明揭示了一系列2-胍基-4-杂环芳基噻唑类化合物，其中杂环芳基取代基选自噻唑基、三唑基、咪唑基和2-烷基、2-氨基和2-羧酰胺衍生物。这些新型化合物具有抗分泌作用和组胺H.sub.2拮抗剂作用，可用于治疗胃酸过多和消化性溃疡。本发明还揭示了包含这些新型化合物的制药组合物以及使用这些化合物治疗胃酸过多和消化性溃疡的方法。还描述了制备新型抗分泌化合物的新型中间体。
• 2-guanidino-4-heteroarylthiazoles
  申请人：Pfizer Inc.

  公开号：US04590299A1

  公开（公告）日：1986-05-20

  A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

  本发明揭示了一系列2-胍基-4-杂环芳基噻唑化合物，其中杂环芳基取代基选自噻唑基、三唑基、咪唑基和2-烷基、2-氨基和2-羧酰胺衍生物。这些新型化合物具有抗分泌作用和组胺H.sub.2 拮抗剂活性，可用于治疗胃酸过多和消化性溃疡。本发明还揭示了含有这些新型化合物的制药组合物以及使用这些化合物治疗胃酸过多和消化性溃疡的方法。还描述了制备新型抗分泌化合物的新型中间体。
• [EN] ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS<br/>[FR] AGENTS THÉRAPEUTIQUES ANTIBACTÉRIENS ET AGENTS PROPHYLACTIQUES
  申请人：VYOME BIOSCIENCES PVT LTD

  公开号：WO2017017631A3

  公开（公告）日：2017-04-06